Skip to main content

Research News

Crack GPAT — Prepare for GPAT Online 
  • A jump through time – new technique rewinds the age of skin cells by 30 years

    Research from the Babraham Institute has developed a method to ‘time jump’ human skin cells by 30 years, turning back the ageing clock for cells without losing their specialised function. Work by researchers in the Institute’s Epigenetics research programme has been able to partly restore the function of older cells, as well as rejuvenating the molecular measures of biological age. The research is published today in the journal eLife and whilst at an early stage of exploration, it could revolutionise regenerative medicine.

  • Unlocking a cure for carbon monoxide poisoning

    Carbon monoxide is an odorless and colorless gas made when fossil fuels burn incompletely. It’s also a silent killer.

    According to the Centers for Disease Control (CDC), more than 400 deaths and 20,000 ER visits can be attributed to carbon monoxide poisoning every year. The most common carbon monoxide (CO) poisoning symptoms are headache, dizziness, weakness, upset stomach, vomiting, chest pain, and confusion. Because it mimics the flu, people may experience symptoms without realizing the danger.

  • Aspirin Does Not Cut Risk in Non-Obstructive Coronary Artery Disease

    Aspirin therapy, as opposed to statin use, for non-obstructive coronary artery disease does not reduce major cardiovascular events, according to a new study published in the journal Radiology: Cardiothoracic Imaging.

  • Zydus Lifesciences publishes phase 3 results of research molecule, Desidustat

    Zydus Lifesciences announced the publication of two manuscripts detailing the DREAM-ND and DREAM-D Phase 3 study results of Desidustat, a novel HIF-PH inhibitor in the prestigious American Journal of Nephrology.

  • From cell fat to cell fate

    How does a cell “decide” what type of cell to become? The question of “cell fate” has been explored for decades now, especially in the context of stem cell biology, but there are still gaps in our understanding. For example, any multicellular organism is made up of different cell types that play specific roles, while they all work together to sustain the organism as a whole.

  • Novel therapeutic agents may reduce the oncogenesis of metastatic prostate cancer

    Researchers have found that treating prostate cancer cells with novel cyclin-dependent kinase 19 (CDK19) and homologous cyclin-dependent kinase 8 (CDK8) inhibitors reduces their potential to migrate into and invade surrounding structures. These molecules may be used as single or combination therapy for patients with advanced disease to prevent and treat metastatic spread. The results appear in The American Journal of Pathology, published by Elsevier.

  • Tumors partially destroyed with sound don’t come back

    Noninvasive sound technology developed at the University of Michigan breaks down liver tumors in rats, kills cancer cells and spurs the immune system to prevent further spread an advance that could lead to improved cancer outcomes in humans.  By destroying only 50% to 75% of liver tumor volume, the rats’ immune systems were able to clear away the rest, with no evidence of recurrence or metastases in more than 80% of animals.

  • Newly identified cell type could be the key to restoring damaged salivary glands

    Scientists at Scripps Research and the National Institute of Dental and Craniofacial Research have discovered a special type of cell that resides in salivary glands and is likely crucial for oral health.

  • Researchers Identify a New Treatment for Metabolic Syndrome

    Metabolic syndrome increases a person’s risk for diabetes, heart disease, and stroke, and includes conditions such as obesity, high blood pressure and high blood sugar. In a recent mouse-model study, published in Cell Metabolism, researchers at University Hospitals (UH), Harrington Discovery Institute at UH, and Case Western Reserve University have furthered their progress to develop a drug to treat metabolic syndrome by identifying a receptor that controls appetite and body weight.

  • SARS-CoV-2 : Neutralization of BA.1 and BA.2 by Therapeutic Monoclonal Antibodies

    The SARS-CoV-2 Omicron BA.1 sublineage has been supplanted in many countries by the BA.2 sublineage. Although Omicron is responsible for less severe forms in the general population, immunocompromised people are still at higher risk of developing severe forms of COVID-19. Several monoclonal antibodies are currently available in clinical practice as a preventive treatment for these patients.

Subscribe to Research News